Features of the use of genetic engineering biological drugs in the treatment of patients with Crohn’s disease

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background. Genetically engineered biological drugs (GEBDs) have now become the drugs of choice for the treatment of inflammatory bowel diseases (IBD) and have been successfully used since their discovery. This is due to their ability to effectively influence both the IBD pathogenetic mechanisms and symptoms. For the effective and safe use of biological drugs, it is necessary to comply with the indications and rules for their use, and irrational prescription and use of biological drugs can lead to side effects.

Description of a series of clinical cases. The article presents a clinical case of a complicated course of Crohn’s disease (CD) in a young patient, reflects the features of diagnosis and course, and treatment tactics for CD. The problem of loss of response to biological therapy and management features are revealed.

Conclusion. The ability to provide timely and high-tech medical care using modern physical therapy makes it possible to avoid the development of surgical complications for a long time and slow down the progression of IBD.

Texto integral

Acesso é fechado

Sobre autores

Nina Fadeeva

Loginov Moscow Clinical Scientific and Practical Center; Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department

Autor responsável pela correspondência
Email: n.fadeeva@mknc.ru
ORCID ID: 0000-0002-0524-2514

Associate Professor, Department of Gastroenterology

Rússia, Moscow; Moscow

O. Knyazev

Loginov Moscow Clinical Scientific and Practical Center; Ryzhikh National Medical Research Center of Coloproctology

Email: n.fadeeva@mknc.ru
ORCID ID: 0000-0001-7250-0977
Rússia, Moscow; Moscow

D. Bordin

Loginov Moscow Clinical Scientific and Practical Center; Tver State Medical University; A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: n.fadeeva@mknc.ru
ORCID ID: 0000-0003-2815-3992
Scopus Author ID: 6602087114
Researcher ID: M-4708-2017
Rússia, Moscow; Tver; Moscow

K. Nikolskaya

Loginov Moscow Clinical Scientific and Practical Center; Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department

Email: n.fadeeva@mknc.ru
ORCID ID: 0000-0002-1477-888X
Scopus Author ID: 57191748544
Rússia, Moscow; Moscow

S. Chudnykh

Loginov Moscow Clinical Scientific and Practical Center; A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: n.fadeeva@mknc.ru
ORCID ID: 0000-0001-6677-7830
Rússia, Moscow; Moscow

N. Dashkina

Loginov Moscow Clinical Scientific and Practical Center; Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department

Email: n.fadeeva@mknc.ru
ORCID ID: 0009-0001-6455-4921
Rússia, Moscow; Moscow

G. Artykova

Loginov Moscow Clinical Scientific and Practical Center; Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department

Email: n.fadeeva@mknc.ru
ORCID ID: 0009-0007-5907-1355
Rússia, Moscow; Moscow

E. Aliev

Loginov Moscow Clinical Scientific and Practical Center; Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department

Email: n.fadeeva@mknc.ru
ORCID ID: 0009-0007-4715-9771
Rússia, Moscow; Moscow

Bibliografia

  1. Хатьков И.Е., Парфенов А.И., Князев О.В. и др. Воспалительные заболевания кишечника в практике терапевта и хирурга. М.: Вита-ПРЕСС, 2017. [Khatkov I.E., Parfenov A.I., Knyazev O.V. and others. Inflammatory bowel diseases in the practice of therapists and surgeons. M.: Vita-PRESS, 2017. (In Russ.)].
  2. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–53.
  3. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.
  4. Sandborn W.J., Feagan B.G., Rutgeerts P., et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.
  5. Hindryckx P., Vande Casteele N., Novak G., et al. The Expanding Therapeutic Armamentarium for Inflammatory bowel disease: how to choose the right drug[s] for our patients? J Crohn’s Colitis. 2018;12(1):105–19.
  6. Armuzzi A., Ardizzone S., Biancone L., et al. Digestive and liver disease. Dig Liver Dis. 2018;50(7):653–60.
  7. Giulia R., Bindia J. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Translat Gastroenterol. 2016;7:e135. doi: 10.1038/ctg.2015.63.
  8. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–49.
  9. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33.
  10. Colombel J.-F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
  11. Nicholas A.,Graham A. Heap et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019(5):341–53. doi: 10.1016/S2468-1253(19)30012-3.
  12. Geert R., Panaccione R., Higgins P.D., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol.2011;106(2): 199–212.
  13. STELARA (ustekinumab) injection, for subcutaneous or intravenous use. Prescribing Information and Summary of Product Characteristics. Janssen Biotech, Inc., 2018.
  14. Feagan B.G., Sandborn W.J., Gasink C., et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60.
  15. Sandborn W.J., Rutgeerts P., Gasink C., et al. Longterm efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018; 4(1):65–77.
  16. Li K., Chan D., Pollack P., et al. Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn’s disease. Gastroenterology. 2017; 152(1):595.
  17. Князев О.В., Никольская К.А., Фадеева Н.А. и др. Эффективность и безопасность устекинумаба у пациентов с воспалительными заболеваниями кишечника в реальной клинической практике. Эффективная фармакотерапия. 2021;17(39):40–7. [Knyazev O.V., Nikolskaya K.A., Fadeeva N.A. et al. Efficacy and safety of ustekinumab in patients with inflammatory bowel diseases in real clinical practice. Effective pharmacotherapy. 2021;17(39):40–7. (In Russ.)].

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
2. Fig.1.

Baixar (50KB)
3. Fig.3.

Baixar (42KB)
4. Fig.3.

Baixar (36KB)

Declaração de direitos autorais © Bionika Media, 2023

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies